FIBROBIOLOGICS, INC. (FBLG)
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
Perk Secures $300 Million Credit Facility to Accelerate Global Growth of Its AI-Native Platform
Ollie’s Bargain Outlet Holdings, Inc. Announces First Quarter Fiscal 2026 Results
Emerita Announces Appointments of New Independent Director and Corporate Secretary
SweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This Summer
Destination XL Group, Inc. Reports First Quarter Financial Results
Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
Wellington Management to Acquire Hartford Funds from The Hartford
Cognyte Reports First Quarter Fiscal Year 2027 Financial Results
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress